Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: adenocarcinoma versus squamous cell carcinoma

被引:3
|
作者
Soetandyo, Noorwati [1 ]
Hanafi, Arif Riswahyudi [2 ]
Agustini, Sri [1 ]
Sinulingga, Dian Triana [3 ]
机构
[1] Dharmais Natl Canc Ctr Hosp, Dept Hematol & Med Oncol, Jakarta, Indonesia
[2] Dharmais Natl Canc Ctr Hosp, Dept Pulmonol, Jakarta, Indonesia
[3] Dharmais Natl Canc Ctr Hosp, Jakarta, Indonesia
关键词
chemotherapy; histology; lung cancer; prognosis; BODY-MASS INDEX; SURVIVAL; EFFICACY; MORTALITY; OUTCOMES; SMOKING;
D O I
10.13181/mji.oa.203787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In Indonesia, lung cancer is one of the most prevalent solid cancer with the highest mortality rate. However, studies to identify prognostic factors associated with mortality are lacking. Thus, this study was aimed to determine the association of histological subtypes and prognosis of advanced stage non-small-cell lung cancer (NSCLC) patients receiving chemotherapy. METHODS This study focused on a retrospective cohort consisting of 60 patients with advanced stage NSCLC and treated with chemotherapy. Patients with NSCLC stage IIIB or stage IV, age >= 18 years, and good performance status were recruited. The outcomes were one-year mortality and treatment response. Gender, age, body mass index, staging, and performance status were evaluated. Chi-square and Fisher's exact tests were used. RESULTS Two common histological subtypes, adenocarcinoma (68.3%) and squamous cell carcinoma (31.7%), were observed among all subjects. Four patients (6.7%) died during one-year observation period. Mortality rate was higher in squamous cell carcinoma (10.5%) patients than in adenocarcinoma (4.9%). Underweight patients had higher risk of death (relative risk [RR] = 1.09, 95% confidence interval [CI] = 1.00-1.19) and disease progression (RR = 1.30, 95% CI = 1.12-1.51). In adenocarcinoma, metastasis was a risk for progressive disease (RR = 1.35, 95% CI = 1.09-1.66). In squamous cell carcinoma, men had a lower risk of disease progression (RR = 0.11, 95% CI = 0.03-0.41). CONCLUSIONS Squamous cell carcinoma had comparable one-year mortality and disease progression rate with adenocarcinoma type in advanced stage NSCLC. However, underweight patients had a higher risk of mortality and disease progression.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
  • [21] Efficacy of tropisetron in patients with advanced non-small-cell lung cancer receiving adjuvant chemotherapy with carboplatin and taxanes
    Tsavaris, N.
    Kosmas, C.
    Kopterides, P.
    Vadiaka, M.
    Kosmas, N.
    Skopelitis, H.
    Karadima, D.
    Kolliokosta, G.
    Tzima, E.
    Loukeris, D.
    Pagouni, E.
    Batziou, E.
    Xyla, V.
    Koufos, C.
    EUROPEAN JOURNAL OF CANCER CARE, 2008, 17 (02) : 167 - 173
  • [22] Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer
    Menter, Alex R.
    Carroll, Nikki M.
    Sakoda, Lori C.
    Delate, Thomas
    Hornbrook, Mark C.
    Jain, Rakesh K.
    Kushi, Lawrence H.
    Quinn, Virginia P.
    Ritzwoller, Debra P.
    CLINICAL LUNG CANCER, 2017, 18 (02) : 189 - +
  • [23] CHEMOTHERAPY OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG-CARCINOMA
    LIU, RJ
    SEMINARS IN ONCOLOGY, 1993, 20 (04) : 296 - 301
  • [24] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
    Paz-Ares, L.
    Luft, A.
    Vicente, D.
    Tafreshi, A.
    Gumus, M.
    Mazieres, J.
    Hermes, B.
    Senler, F. Cay
    Csoszi, T.
    Fulop, A.
    Rodriguez-Cid, J.
    Wilson, J.
    Sugawara, S.
    Kato, T.
    Lee, K. H.
    Cheng, Y.
    Novello, S.
    Halmos, B.
    Li, X.
    Lubiniecki, G. M.
    Piperdi, B.
    Kowalski, D. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2040 - 2051
  • [25] Chemotherapy of non-small-cell lung carcinoma
    LeChevalier, T
    PRESSE MEDICALE, 1996, 25 (35): : 1699 - 1703
  • [26] Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer
    Bondarenko, Igor M.
    Ingrosso, Antonella
    Bycott, Paul
    Kim, Sinil
    Cebotaru, Cristina L.
    BMC CANCER, 2015, 15
  • [27] Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer
    Zhang, Zixuan
    Xiao, Yi
    Zhao, Jing
    Chen, Minjiang
    Xu, Yan
    Zhong, Wei
    Xing, Jia
    Wang, Mengzhao
    RESPIROLOGY, 2016, 21 (03) : 519 - 525
  • [29] Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients
    Gao, Ying
    Gao, Fei
    Ma, Jin-lu
    Zhang, Xiao-zhi
    Li, Yi
    Song, Li-ping
    Zhao, Dong-li
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 1189 - 1194
  • [30] Induction chemotherapy in early stage non-small-cell lung cancer
    Katherine M. W. Pisters
    Current Oncology Reports, 2003, 5 (4) : 307 - 308